BriaCell Therapeutics (TSE:BCT) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Phase I/II study “A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab” tests BriaCell Therapeutics’ lead breast cancer regimen with a checkpoint inhibitor. It targets patients whose cancer has returned or spread after standard care, aiming to show if this combo can offer a new option in a hard to treat setting.
The trial uses SV-BR-1-GM, a cell based immunotherapy, alongside low dose chemotherapy and interferon to prime the immune system. It then adds retifanlimab, a PD-1 checkpoint inhibitor, designed to release immune brakes and help the body attack breast cancer more effectively.
The study is interventional and randomized, with patients assigned to different timing of the same combo. It is open label, so both doctors and patients know what they get, and the main goal is treatment focused, looking first at safety, then at early signs of benefit like tumor response.
The trial began after first submission on 2017-10-23 and has now reached a Completed status, which means core data collection is done. The most recent update was filed on 2026-03-24, signaling that BriaCell has refreshed key information and may be preparing or refining the data set that investors are watching.
For BCT, a completed Phase I/II breast cancer study with an updated record can support the company’s story around its lead asset and strengthen its negotiating position with partners like LumaBridge. Investor sentiment may improve if safety looks clean and early activity is seen, especially versus larger immuno oncology players and other breast cancer innovators that are also chasing combination strategies.
If the study shows even modest, durable responses in heavily pretreated patients, it could justify continued development and help BCT argue for higher valuations or new funding on better terms. The study is now completed with records updated, and further details are available on the ClinicalTrials portal.
To learn more about TSE:BCT’s potential, visit the BriaCell Therapeutics drug pipeline page.